AKRO Share Price Performance
US$53.88
23.87 (79.54%)
Price US$53.88
Share PriceUS$53.88
Akero Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
AKRO Community Narratives
There are no narratives available yet.
Recent AKRO News & Updates
Akero Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.55
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 3.5%
Akero Therapeutics, Inc. Competitors
Snowflake Analysis
About AKRO
- Founded
- 2017
- Employees
- 67
- CEO
- WebsiteView website
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 5.1%
- 1 Year: 13.4%
- Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. In the last year, the market is actually up 13%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›